Japan/Asia Long-Short, LightStream Research

Mio Kato

Japan/Asia Long-Short

Japanese and Asian equity long/short strategies

Uzabase

Specialising in Japanese and Asian equity long/short strategies with a focus on rigorous, but targeted quantitative analysis to temper evaluations of company strategy, potential and vision. At Uzabase, our team of analysts provides coverage of industry dynamics with a local Asian flavour on Speeda, our financial information platform. Going forward we are aiming to channel our focus toward thematic research on emerging industries and company research.

Equity Bottom-Up

Sysmex stock is up 3.4x since the end of 2012 (36% price CAGR) when easing by the BOJ started a strong JPY depreciation trend, helping the company double overseas sales and drive OPM from 15.0% in FY2013 to 22.5% in FY2016.With overseas sales having peaked in 4QFY2016 and fallen to just above 3QFY2015 levels in 2QFY2017, we are concerned that the company's 32x PE and 24x EV/OP multiples are looking extremely rich. With the company having successfully exploited global opportunities in the hematology diagnostics space in which it is so strong, the hurdles for both revenue expansion and operating margin accretion are now that much higher.If profit growth slows from 30% a year to 10% a year (cf. a roughly 6% industry topline growth rate), would 24x PE and 18x EV/OP (22% downside potential) really be too cheap?

Sysmex stock is up 3.4x since the end of 2012 (36% price CAGR) when easing by the BOJ started a strong JPY depreciation trend, helping the company double overseas sales and drive OPM from 15.0% in FY2013 to 22.5% in FY2016.With overseas sales having peaked in 4QFY2016 and fallen to just above 3QFY2015 levels in 2QFY2017, we are concerned that the company's 32x PE and 24x EV/OP multiples are looking extremely rich. With the company having successfully exploited global opportunities in the hematology diagnostics space in which it is so strong, the hurdles for both revenue expansion and operating margin accretion are now that much higher.If profit growth slows from 30% a year to 10% a year (cf. a roughly 6% industry topline growth rate), would 24x PE and 18x EV/OP (22% downside potential) really be too cheap?

Japan Small Cap Tour: Overseas Expansion Stalling at Sysmex?

Asia Healthcare Analyst, Pathology Associates Limited

Dion Stéfan Büchner M.D., FCAP

Asia Healthcare Analyst

Pathology Associates Limited

Thematic (Sector/Industry)

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment landscape for non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), myeloadysplastic syndrome (MDS) and acute myeloid leukemia (AML).Data on several novel programs were presented; we review select companies based on our standard abstract assessment methodology. We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria…

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment landscape for non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), myeloadysplastic syndrome (MDS) and acute myeloid leukemia (AML).Data on several novel programs were presented; we review select companies based on our standard abstract assessment methodology. We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria…

American Society of Hematology- (ASH) Annual Conference (2016) Review

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at the upcoming American Society of Hematology (<a href="http://www.hematology.org/Annual-Meeting/" target="_blank">ASH – 2016</a>) conference in San Diego this weekend.We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria (mechanism of action, clinical phase, indication, route of administration, study design, safety profile and efficacy profile) and assign weight to each criterion...

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at the upcoming American Society of Hematology (ASH – 2016) conference in San Diego this weekend.We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria (mechanism of action, clinical phase, indication, route of administration, study design, safety profile and efficacy profile) and assign weight to each criterion...

American Society of Hematology (ASH) -Annual Conference (2016) Preview

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/016/178/original/download%20%281%29.jpg?1478808170" class="editor-image img-responsive" data-smartkarma-image-id="16178"></figure><div class="content-caption">(I thought it was a reality show till I was shown the Oval Office today!)</div>Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare and pharmaceutical sector. Broadly, Trump's policy on healthcare has focused on two issues: allowing Medicare to negotiate drug prices directly with the drug companies and repealing Obamacare.<div class="content-highlight">Drug Pricing and Trump:</div>Allowing Medicare and similar U.S. government programs to…

(I thought it was a reality show till I was shown the Oval Office today!)Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare and pharmaceutical sector. Broadly, Trump's policy on healthcare has focused on two issues: allowing Medicare to negotiate drug prices directly with the drug companies and repealing Obamacare.Drug Pricing and Trump:Allowing Medicare and similar U.S. government programs to…

President Trump and Healthcare (And Pharma) Sector: What's Next?

<a href="https://www.smartkarma.com/entities/10370" target="_blank" data-smartkarma-citation="entities:10370:1">Acadia Pharmaceuticals Inc (ACAD US)</a>, our portfolio company announced the initiation of a phase 2 study of Nuplazid in Alzheimer's related agitation, an area of great unmet need. Alzheimer's related agitation could be even a larger potential market than Alzheimer-related psychosis (ADP). The drug is already in a phase 2 trial for ADP and results are expected later this year (which could provide an upward boost to the stock). We recommend accumulating the stock on current weakness. Our price…

 Acadia Pharmaceuticals Inc (ACAD US), our portfolio company announced the initiation of a phase 2 study of Nuplazid in Alzheimer's related agitation, an area of great unmet need. Alzheimer's related agitation could be even a larger potential market than Alzheimer-related psychosis (ADP). The drug is already in a phase 2 trial for ADP and results are expected later this year (which could provide an upward boost to the stock). We recommend accumulating the stock on current weakness. Our price…

Some Actionable Ideas in the Biotechnology and Pharmaceutical Sector: October 31 Sector Update

Japan

SYSMEX CORPORATION manufactures reagents and equipment for clinical tests including hematologic (blood) and immune tests. The Company also develops, manufactures, and trades particle analyzers such as blood coagulation analyzer and related software. Manufacturing and sales outside Japan include the United States, EMEA, China and Asia Pacific regions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sysmex (6869 JT)

Japan Small Cap Tour: Overseas Expansion Stalling at Sysmex?

Sysmex stock is up 3.4x since the end of 2012 (36% price CAGR) when easing by the BOJ started a strong JPY depreciation trend, helping the company...

Mio Kato

American Society of Hematology- (ASH) Annual Conference (2016) Review

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...

Dion Stéfan Büchner M.D., FCAP

American Society of Hematology (ASH) -Annual Conference (2016) Preview

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at...

Dion Stéfan Büchner M.D., FCAP

President Trump and Healthcare (And Pharma) Sector: What's Next?

Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare...

Dr. Bhavneesh Sharma, MD, MBA

Some Actionable Ideas in the Biotechnology and Pharmaceutical Sector: October 31 Sector Update

Acadia Pharmaceuticals Inc (ACAD US), our portfolio company announced the initiation of a phase 2 study of Nuplazid in Alzheimer's related...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)